Genesis Co-Founder Michael Watkins Is Named One of the World’s Most Influential Business Thinkers
10.12.2019 17:07:00 EET | Business Wire | Press release
Michael Watkins, leadership transitions expert and best-selling author of the classic onboarding reference The First 90 Days, was named one of the world’s most influential business thinkers by Thinkers50. Among those also included in the prestigious rankings were W. Chan Kim, Renée Mauborgne, Roger Martin, Amy Edmondson, and Daniel Pink.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191210005452/en/
The First 90 Days and Master Your Next Move author Michael Watkins named one of the world’s most influential business thinkers. (Photo: Business Wire)
Thinkers50 identifies and ranks the top 50 management thinkers globally and announces them at their biannual Awards Gala, dubbed “the Oscars of Management Thinking” by the Financial Times. This year’s Thinkers50 rankings are the most diverse yet, with 19 women in the top 50, and 14 nationalities represented overall.
On receiving the news that he made the list Watkins said, “It is very gratifying to be included in the Thinkers50 rankings. To have the ideas to which I have devoted my career endorsed in this way is an honor. It also highlights the importance for leaders to learn how to navigate diverse career transitions and for companies to provide needed support for onboarding.”
Michael Watkins
Best known for his international best-seller The First 90 Days in which he outlines his framework for navigating successful career transitions, Watkins is the cofounder of Boston, MA-based leadership development consultancy, Genesis Advisers. He is the author of eleven books published by Harvard Business Review Press including Master Your Next Move: The Essential Companion to The First 90 Days (HBR Press, April 2019), as well as numerous articles on the subjects of leadership, organizational change, and negotiation. He is professor of Leadership and Organizational Change at the IMD Business School where he teaches two programs based on his First 90 Days® onboarding framework, as well as his Seven Seismic Shifts™ framework for managing the transition to enterprise leader. Prior to IMD, Watkins taught at INSEAD, Harvard Business School and Harvard University, where he earned his PhD in Decision Sciences.
Thinkers50
Launched in 2001, Thinkers50 was the first-ever global ranking of management thinkers. The List has been published every two years since and remains the premier ranking of its kind. Since its founding, the scope of Thinkers50 has broadened to include a range of activities that support the mission of providing innovative access to powerful business and management ideas.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191210005452/en/
Contact information
Michol J. Munns
Director of Marketing and Communications
Michol.munns@genesisadvisers.com
https://www.genesisadvisers.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release
With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
